Shares of AstraZeneca Pharma India today surged nearly 11 per cent after the company received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.

The stock soared 7.63 per cent to end at Rs 1,840.75 on BSE. During the day, it zoomed 10.74 per cent to Rs 1,894 -- its 52-week high.

At NSE, shares of the company jumped 10.63 per cent to settle at Rs 1,890.

The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing yesterday.

The tablets are a patented product of the AstraZeneca group, it added.